{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:21:48Z","timestamp":1740144108151,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T00:00:00Z","timestamp":1638576000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000738","name":"u.s. department of veterans affairs","doi-asserted-by":"publisher","award":["13-314"],"award-info":[{"award-number":["13-314"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Medication adherence in gout is suboptimal, and the lack of\u00a0effective interventions to address it presents a huge challenge. Medication adherence and gout outcomes are worse in racial\/ethnic minorities. The objective of this paper was to provide the details of the study protocol for randomized, controlled trial (RCT) in African Americans (AAs) with gout that will test the effectiveness of a culturally appropriate gout storytelling intervention.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The SToRytelliing to Improve Disease outcomes in Gout (STRIDE-GO) study will be a 12-month, multicenter, open-label RCT that will assess the effect of a culturally appropriate gout storytelling in at least 300 AA veterans with gout. Participants will be randomized to gout-storytelling intervention vs. a stress reduction video in a 1:1 ratio. The primary outcome is urate-lowering therapy (ULT) adherence measured with MEMSCap\u2122, an electronic monitoring system (efficacy, 6 months; sustenance of efficacy, 12 months). Secondary outcomes include gout flares, serum urate (SU), gout-specific health-related quality of life [HRQOL], self-reported ULT adherence, patient satisfaction with treatment, and patient understanding of the intervention. AA veterans with gout who met the 1977 Preliminary American College of Rheumatology (ACR) classification criteria for gout, currently prescribed an oral ULT medication (allopurinol or febuxostat) for at least 6 months, and not using a pillbox to redistribute their medications, will be invited to an in-person study visit. After the study coordinators obtain informed consent, and ensure that participants meet the inclusion criteria, the eligible participants will be provided with their current ULT in a MEMSCap\u2122 bottle for the 1-month run-in period and asked to return to the clinic in 1 month. ULT adherence with MEMSCap\u2122 will be recorded at a 1-month return visit. Interested participants will complete the baseline assessments, randomized using the computerized system to either gout-storytelling intervention or a stress reduction intervention video arm and watch the respective video in-clinic. Patients will be interviewed on the phone at 2 and 4 months regarding the viewing of the videos at home at each time. Participants will be assessed in-clinic at 3, 6, 9, and 12 months; MEMSCap\u2122 data and patient surveys will be captured at each visit. For any missed visit, assessments will be completed on the phone and MEMSCap\u2122 data captured at the next in-clinic visit.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The study will assess the efficacy of a behavioral intervention to improve ULT adherence in minority populations with gout.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> NCT 02741700. Registered on 14 September 2018<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-021-05847-9","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T19:02:32Z","timestamp":1638644552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SToRytelliing to Improve Disease outcomes in Gout (STRIDE-GO) in African American veterans with gout: a trial study protocol"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3485-0006","authenticated-orcid":false,"given":"Jasvinder A.","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,4]]},"reference":[{"issue":"6","key":"5847_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/01.mlr.0000163641.86870.af","volume":"43","author":"MC Sokol","year":"2005","unstructured":"Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521\u201330. https:\/\/doi.org\/10.1097\/01.mlr.0000163641.86870.af.","journal-title":"Med Care"},{"issue":"4","key":"5847_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1592\/phco.28.4.437","volume":"28","author":"BA Briesacher","year":"2008","unstructured":"Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437\u201343. https:\/\/doi.org\/10.1592\/phco.28.4.437.","journal-title":"Pharmacotherapy"},{"issue":"10","key":"5847_CR3","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136\u201341. https:\/\/doi.org\/10.1002\/art.30520.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5847_CR4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/art.22767","volume":"57","author":"JA Singh","year":"2007","unstructured":"Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57(5):822\u20139. https:\/\/doi.org\/10.1002\/art.22767.","journal-title":"Arthritis Rheum"},{"key":"5847_CR5","first-page":"387","volume-title":"Patient compliance in medical practice and clinical trials","author":"J Cramer","year":"1991","unstructured":"Cramer J. Identifying and improving compliance patterns. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press; 1991. p. 387\u201392."},{"issue":"2","key":"5847_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s10488-010-0304-1","volume":"38","author":"JE Zeber","year":"2011","unstructured":"Zeber JE, Miller AL, Copeland LA, McCarthy JF, Zivin K, Valenstein M, et al. Medication adherence, ethnicity, and the influence of multiple psychosocial and financial barriers. Adm Policy Ment Health. 2011;38(2):86\u201395. https:\/\/doi.org\/10.1007\/s10488-010-0304-1.","journal-title":"Adm Policy Ment Health"},{"key":"5847_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000011.pub2","volume":"4","author":"RB Haynes","year":"2005","unstructured":"Haynes RB, Yao X, Degani A, Kripalani S, Garg A, McDonald HP. Interventions to enhance medication adherence. Cochrane Database Syst Rev. 2005;4:CD000011. https:\/\/doi.org\/10.1002\/14651858.CD000011.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"5847_CR8","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/art.1780380508","volume":"38","author":"MC Hochberg","year":"1995","unstructured":"Hochberg MC, Thomas J, Thomas DJ, Mead L, Levine DM, Klag MJ. Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum. 1995;38(5):628\u201332. https:\/\/doi.org\/10.1002\/art.1780380508.","journal-title":"Arthritis Rheum"},{"issue":"10 Suppl","key":"5847_CR9","first-page":"S772","volume":"64","author":"K Coley","year":"2012","unstructured":"Coley K, Saul M, Pater K. Relationship between race, uric acid levels, urate-lowering therapy and resource use in patients with gout. Arthritis & Rheumatism. 2012;64(10 Suppl):S772.","journal-title":"Arthritis & Rheumatism"},{"issue":"5","key":"5847_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/ard.2007.076182","volume":"67","author":"DH Solomon","year":"2008","unstructured":"Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67(5):609\u201313. https:\/\/doi.org\/10.1136\/ard.2007.076182.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5847_CR11","first-page":"498","volume":"35","author":"E Krishnan","year":"2008","unstructured":"Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol. 2008;35(3):498\u2013501.","journal-title":"J Rheumatol"},{"issue":"2","key":"5847_CR12","doi-asserted-by":"publisher","first-page":"R82","DOI":"10.1186\/ar4524","volume":"16","author":"JA Singh","year":"2014","unstructured":"Singh JA. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. Arthritis Res Ther. 2014;16(2):R82. https:\/\/doi.org\/10.1186\/ar4524.","journal-title":"Arthritis Res Ther"},{"key":"5847_CR13","unstructured":"Maynard W, Janet A, McAdams MN, Baer AC, Gelber A, Coresh J. Racial differences in gout risk and uric acid levels in both men and women in the Atherosclerosis Risk in Communities (ARIC) Study. [abstract]. Arthritis Rheum 2010;62 Suppl 10:1556."},{"issue":"5","key":"5847_CR14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1192\/apt.bp.106.003194","volume":"13","author":"AJ Mitcheli","year":"2007","unstructured":"Mitcheli AJ, Selmes T. Why don\u2019t patients take their medication? Reasons and solutions in psychiatry. Adv Psyhiatric Treatment. 2007;13(5):336\u201346. https:\/\/doi.org\/10.1192\/apt.bp.106.003194.","journal-title":"Adv Psyhiatric Treatment"},{"issue":"3","key":"5847_CR15","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.140588","volume":"42","author":"N Rashid","year":"2015","unstructured":"Rashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, et al. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol. 2015;42(3):504\u201312. https:\/\/doi.org\/10.3899\/jrheum.140588.","journal-title":"J Rheumatol"},{"issue":"7","key":"5847_CR16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925\u201334. https:\/\/doi.org\/10.4065\/81.7.925.","journal-title":"Mayo Clin Proc"},{"issue":"22","key":"5847_CR17","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1001\/jama.1989.03420220087032","volume":"261","author":"JA Cramer","year":"1989","unstructured":"Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261(22):3273\u20137. https:\/\/doi.org\/10.1001\/jama.1989.03420220087032.","journal-title":"JAMA"},{"issue":"3","key":"5847_CR18","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895\u2013900. https:\/\/doi.org\/10.1002\/art.1780200320.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"5847_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archinte.165.7.742","volume":"165","author":"HK Choi","year":"2005","unstructured":"Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med. 2005;165(7):742\u20138. https:\/\/doi.org\/10.1001\/archinte.165.7.742.","journal-title":"Arch Intern Med"},{"issue":"9417","key":"5847_CR20","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","volume":"363","author":"HK Choi","year":"2004","unstructured":"Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363(9417):1277\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(04)16000-5.","journal-title":"Lancet"},{"issue":"4","key":"5847_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.amjmed.2013.12.019","volume":"127","author":"T Neogi","year":"2014","unstructured":"Neogi T, Chen C, Niu J, Chaisson C, Hunter DJ, Zhang Y. Alcohol quantity and type on risk of recurrent gout attacks: an internet-based case-crossover study. Am J Med. 2014;127(4):311\u20138. https:\/\/doi.org\/10.1016\/j.amjmed.2013.12.019.","journal-title":"Am J Med"},{"issue":"12","key":"5847_CR22","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/MLR.0b013e318269e121","volume":"50","author":"CI Voils","year":"2012","unstructured":"Voils CI, Maciejewski ML, Hoyle RH, Reeve BB, Gallagher P, Bryson CL, et al. Initial validation of a self-report measure of the extent of and reasons for medication nonadherence. Med Care. 2012;50(12):1013\u20139. https:\/\/doi.org\/10.1097\/MLR.0b013e318269e121.","journal-title":"Med Care"},{"issue":"12","key":"5847_CR23","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3899\/jrheum.080506","volume":"35","author":"JD Hirsch","year":"2008","unstructured":"Hirsch JD, Lee SJ, Terkeltaub R, et al. Evaluation of an instrument assessing influence of gout on health-related quality of life. J Rheumatol. 2008;35(12):2406\u201314. https:\/\/doi.org\/10.3899\/jrheum.080506.","journal-title":"J Rheumatol"},{"issue":"11","key":"5847_CR24","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.3899\/jrheum.100336","volume":"37","author":"JA Singh","year":"2010","unstructured":"Singh JA, Mahowald ML, Noorbaloochi S. Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial. J Rheumatol. 2010;37(11):2377\u201386. https:\/\/doi.org\/10.3899\/jrheum.100336.","journal-title":"J Rheumatol"},{"issue":"2","key":"5847_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1600-0846.2010.00431.x","volume":"16","author":"SM Greenlaw","year":"2010","unstructured":"Greenlaw SM, Yentzer BA, O\u2019Neill JL, Balkrishnan R, Feldman SR. Assessing adherence to dermatology treatments: a review of self-report and electronic measures. Skin Res Technol. 2010;16(2):253\u20138. https:\/\/doi.org\/10.1111\/j.1600-0846.2010.00431.x.","journal-title":"Skin Res Technol"},{"issue":"5","key":"5847_CR26","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/art.33483","volume":"64","author":"AL Gaffo","year":"2012","unstructured":"Gaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R, et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum. 2012;64(5):1508\u201317. https:\/\/doi.org\/10.1002\/art.33483.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5847_CR27","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1524-4733.2008.00323.x","volume":"11","author":"MA Ruiz","year":"2008","unstructured":"Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL. Development and validation of the \u201cTreatment Satisfaction with Medicines Questionnaire\u201d (SATMED-Q). Value Health. 2008;11(5):913\u201326. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00323.x.","journal-title":"Value Health"},{"issue":"1","key":"5847_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1471-2288-11-142","volume":"11","author":"J Rejas","year":"2011","unstructured":"Rejas J, Ruiz MA, Pardo A, Soto J. Minimally important difference of the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q). BMC Med Res Methodol. 2011;11(1):142. https:\/\/doi.org\/10.1186\/1471-2288-11-142.","journal-title":"BMC Med Res Methodol"},{"key":"5847_CR29","unstructured":"Laboratory S. An EKF diagnostics company. Uric Acid LiquiColor\u00ae Test (Enzymatic) [online]. In. Boerne. TX Stanbio Laboratory. ."},{"key":"5847_CR30","volume-title":"Patient Education Materials Assessment Tool for Audiovisual Materials (PEMAT-A\/V). (Prepared by Abt Associates, under Contract No. HHSA290200900012I, TO 4). Publication No. 14-0002-EF. In","author":"SJ Shoemaker","year":"2013","unstructured":"Shoemaker SJ, Wolf MS, Brach C. Patient Education Materials Assessment Tool for Audiovisual Materials (PEMAT-A\/V). (Prepared by Abt Associates, under Contract No. HHSA290200900012I, TO 4). Publication No. 14-0002-EF. In. Agency for Healthcare Research and Quality: Rockville, MD; 2013."},{"key":"5847_CR31","volume-title":"Khanna PP, et al","author":"D Khanna","year":"2011","unstructured":"Khanna D, Sarkin AJ. Minimally important differences of the gout impact scale in a randomized controlled trial. In: Khanna PP, et al. Rheumatology (Oxford): Minimally important differences of the gout impact scale in a randomized controlled trial; 2011."},{"issue":"1-3","key":"5847_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.psychres.2007.05.001","volume":"157","author":"PA Nakonezny","year":"2008","unstructured":"Nakonezny PA, Byerly MJ, Rush AJ. Electronic monitoring of antipsychotic medication adherence in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of its reliability and predictive validity. Psychiatry Res. 2008;157(1-3):259\u201363. https:\/\/doi.org\/10.1016\/j.psychres.2007.05.001.","journal-title":"Psychiatry Res"},{"issue":"2","key":"5847_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.euroneuro.2013.11.013","volume":"24","author":"C Brain","year":"2014","unstructured":"Brain C, Sameby B, Allerby K, Lindstr\u00f6m E, Eberhard J, Burns T, et al. Twelve months of electronic monitoring (MEMS(R)) in the Swedish COAST-study: a comparison of methods for the measurement of adherence in schizophrenia. Eur Neuropsychopharmacol. 2014;24(2):215\u201322. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.11.013.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"5847_CR34","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3899\/jrheum.080814","volume":"36","author":"MA Becker","year":"2009","unstructured":"Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273\u201382. https:\/\/doi.org\/10.3899\/jrheum.080814.","journal-title":"J Rheumatol"},{"issue":"1","key":"5847_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","volume":"15","author":"R Halpern","year":"2009","unstructured":"Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15(1):3\u20137. https:\/\/doi.org\/10.1097\/RHU.0b013e3181945d2c.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"5847_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321\u20135. https:\/\/doi.org\/10.1002\/art.20405.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"5847_CR37","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/acr.22336","volume":"66","author":"MA De Vera","year":"2014","unstructured":"De Vera MA, Marcotte G, Rai S, Galo JS, Bhole V. Medication adherence in gout: a systematic review. Arthritis Care Res (Hoboken). 2014;66(10):1551\u20139. https:\/\/doi.org\/10.1002\/acr.22336.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"5847_CR38","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","volume":"47","author":"L Scheepers","year":"2017","unstructured":"Scheepers L, van Onna M, Stehouwer CDA, Singh JA, Arts ICW, Boonen A. Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum. 2017;47(5):689\u2013702. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.09.007.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"5847_CR39","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1353\/hpu.0.0323","volume":"21","author":"DP Scharff","year":"2010","unstructured":"Scharff DP, Mathews KJ, Jackson P, Hoffsuemmer J, Martin E, Edwards D. More than Tuskegee: understanding mistrust about research participation. J Health Care Poor Underserved. 2010;21(3):879\u201397. https:\/\/doi.org\/10.1353\/hpu.0.0323.","journal-title":"J Health Care Poor Underserved"},{"issue":"9","key":"5847_CR40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1046\/j.1525-1497.1999.07048.x","volume":"14","author":"G Corbie-Smith","year":"1999","unstructured":"Corbie-Smith G, Thomas SB, Williams MV, Moody-Ayers S. Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med. 1999;14(9):537\u201346. https:\/\/doi.org\/10.1046\/j.1525-1497.1999.07048.x.","journal-title":"J Gen Intern Med"},{"issue":"11","key":"5847_CR41","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/acr.23202","volume":"69","author":"JA Singh","year":"2017","unstructured":"Singh JA, Herbey I, Bharat A, Dinnella JE, Pullman-Mooar S, Eisen S, et al. Gout self-management in African American veterans: a qualitative exploration of challenges and solutions from patients\u2019 perspectives. Arthritis Care Res (Hoboken). 2017;69(11):1724\u201332. https:\/\/doi.org\/10.1002\/acr.23202.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05847-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-021-05847-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-021-05847-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T19:05:43Z","timestamp":1638644743000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-021-05847-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5847"],"URL":"https:\/\/doi.org\/10.1186\/s13063-021-05847-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"26 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study will be approved by the Institutional Review Board (IRBs) at the Birmingham, St. Louis, and Philadelphia Veterans Affairs Medical Centers. All investigations were conducted in conformity with the ethical principles of research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no financial conflicts related directly to this study. JAS has received consultant fees from Crealta\/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, Practice Point communications, and the National Institutes of Health and the American College of Rheumatology. JAS owns stock options in TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics Tonix Pharmaceuticals Holding Corp., and Charlotte\u2019s Web Holdings, Inc. JAS previously owned stock options in Amarin, Viking, and Moderna Pharmaceuticals. JAS is on the Speaker\u2019s Bureau of Simply Speaking. JAS has received institutional research support from Zimmer Biomet Holdings. JAS received food and beverage payments from Intuitive Surgical Inc.\/Philips Electronics North America. JAS is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organization that develops outcome measures in rheumatology and receives arms-length funding from 8 companies. JAS serves on the FDA Arthritis Advisory Committee. JAS is a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and the Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. JAS previously served as a member of the following committees: member, the American College of Rheumatology\u2019s (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees; the chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and the co-chair of the ACR Criteria and Response Criteria subcommittee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"879"}}